Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Clayton Bettin

Foot and Ankle Surgery Memphis, TN Medical Doctor

NPI 1376861849 CMS profile 1395438

1211 Union Ave, Suite 500, Memphis, TN 38104

Open in the dashboard

General payments

$88,759

84 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Clayton Bettin of Memphis, TN is reported in the CMS Open Payments database as having received $88,759 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,282 19
2024 General $26,630 21
2023 General $50,091 13
2022 General $4,540 9
2021 General $405 6
2020 General $462 2
2019 General $2,349 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Clayton Bettin
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to Clayton Bettin were reported at $4,282. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year Clayton Bettin Foot and Ankle Surgery median Middle half National median
2019 $2,349 $1,327 $279–$5,421 $163
2020 $462 $795 $121–$3,473 $114
2021 $405 $1,289 $201–$4,963 $132
2022 $4,540 $1,539 $270–$6,067 $149
2023 $50,091 $1,117 $257–$5,264 $160
2024 $26,630 $1,064 $235–$4,944 $164
2025 $4,282 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Paragon 28, Inc. $84,721 54 payments
  2. Arthrex, Inc. $997 7 payments
  3. MedShape, Inc. $900 2 payments
  4. Gentleman Orthopedic Solutions $800 3 payments
  5. Stryker Corporation $359 3 payments
  6. Exactech, Inc. $195 3 payments
  7. Crossroads Extremity Systems, LLC $169 1 payment
  8. Sanara MedTech Inc. $165 2 payments
  9. DePuy Synthes Sales Inc. $141 1 payment
  10. Treace Medical Concepts, Inc. $134 1 payment
  11. Other $177 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $70,671 6 payments
  2. Travel and Lodging $13,202 39 payments
  3. Food and Beverage $3,954 37 payments
  4. Education $718 1 payment
  5. Royalty or License $213 1 payment
Products named General payments · program years 2019–2025
  1. PORTFOLIO $77,702 41 payments
  2. Product Portfolio $4,177 7 payments
  3. APEX 3D $1,454 3 payments
  4. GORILLA $578 1 payment
  5. MONSTER $477 1 payment
  6. Bun-Yo-Matic $333 1 payment
  7. INFINITY $284 2 payments
  8. CellerateRx $165 2 payments
  9. Equinoxe $164 1 payment
  10. INBONE $163 1 payment
  11. Other $1,407 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

399

Median for Orthopedic Surgery: 203

Drug cost

$3,221

Median for Orthopedic Surgery: $1,433

Branded share of claims

2.8%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 136 $1,772
Diclofenac Sodium Generic 11 $443
Meloxicam Generic 172 $436
Ondansetron Hcl Generic 32 $391
Tramadol Hcl Generic 37 $122
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $57

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 154 billing codes

Paid by Medicare

$145,388

Medicare's payments for the services billed

Medicare patients

375

Average age 72

Services billed

1,730

234 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Diabetes 41%
Ischemic heart disease 33%
Chronic kidney disease 30%
Depression 23%
Heart failure 21%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record